1
|
Czestkowski W, Krzemiński Ł, Piotrowicz MC, Mazur M, Pluta E, Andryianau G, Koralewski R, Matyszewski K, Olejniczak S, Kowalski M, Lisiecka K, Kozieł R, Piwowar K, Papiernik D, Nowotny M, Napiórkowska-Gromadzka A, Nowak E, Niedziałek D, Wieczorek G, Siwińska A, Rejczak T, Jędrzejczak K, Mulewski K, Olczak J, Zasłona Z, Gołębiowski A, Drzewicka K, Bartoszewicz A. Structure-Based Discovery of High-Affinity Small Molecule Ligands and Development of Tool Probes to Study the Role of Chitinase-3-Like Protein 1. J Med Chem 2024; 67:3959-3985. [PMID: 38427954 DOI: 10.1021/acs.jmedchem.3c02255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2024]
Abstract
Chitinase-3-like-1 (CHI3L1), also known as YKL-40, is a glycoprotein linked to inflammation, fibrosis, and cancer. This study explored CHI3L1's interactions with various oligosaccharides using microscale thermophoresis (MST) and AlphaScreen (AS). These investigations guided the development of high-throughput screening assays to assess interference of small molecules in binding between CHI3L1 and biotinylated small molecules or heparan sulfate-based probes. Small molecule binders of YKL-40 were identified in our chitotriosidase inhibitors library with MST and confirmed through X-ray crystallography. Based on cocrystal structures of potent hit compounds with CHI3L1, small molecule probes 19 and 20 were designed for an AS assay. Structure-based optimization led to compounds 30 and 31 with nanomolar activities and drug-like properties. Additionally, an orthogonal AS assay using biotinylated heparan sulfate as a probe was developed. The compounds' affinity showed a significant correlation in both assays. These screening tools and compounds offer novel avenues for investigating the role of CHI3L1.
Collapse
Affiliation(s)
| | | | | | - Marzena Mazur
- Molecure S.A., Żwirki I Wigury 101, Warsaw 02-089, Poland
| | - Elżbieta Pluta
- Molecure S.A., Żwirki I Wigury 101, Warsaw 02-089, Poland
| | | | | | | | | | | | | | - Rafał Kozieł
- Molecure S.A., Żwirki I Wigury 101, Warsaw 02-089, Poland
| | | | | | - Marcin Nowotny
- Laboratory of Protein Structure, International Institute of Molecular and Cell Biology in Warsaw, Ks. Trojdena 4, Warsaw 02-109, Poland
| | - Agnieszka Napiórkowska-Gromadzka
- Laboratory of Protein Structure, International Institute of Molecular and Cell Biology in Warsaw, Ks. Trojdena 4, Warsaw 02-109, Poland
| | - Elżbieta Nowak
- Laboratory of Protein Structure, International Institute of Molecular and Cell Biology in Warsaw, Ks. Trojdena 4, Warsaw 02-109, Poland
| | | | | | - Anna Siwińska
- Molecure S.A., Żwirki I Wigury 101, Warsaw 02-089, Poland
| | - Tomasz Rejczak
- Molecure S.A., Żwirki I Wigury 101, Warsaw 02-089, Poland
| | | | | | - Jacek Olczak
- Molecure S.A., Żwirki I Wigury 101, Warsaw 02-089, Poland
| | | | | | | | | |
Collapse
|
2
|
Sklepkiewicz P, Dymek BA, Mlacki M, Koralewski R, Mazur M, Nejman-Gryz P, Korur S, Zagozdzon A, Rymaszewska A, von der Thüsen JH, Siwińska AM, Güner NC, Cheda Ł, Paplinska-Goryca M, Proboszcz M, van den Bosch TPP, Górska K, Golab J, Kamiński RM, Krenke R, Golebiowski A, Dzwonek K, Dobrzanski P. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. Eur J Pharmacol 2022; 919:174792. [PMID: 35122869 DOI: 10.1016/j.ejphar.2022.174792] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 01/25/2022] [Accepted: 01/26/2022] [Indexed: 12/13/2022]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and eventually fatal lung disease with a complex etiology. Approved drugs, nintedanib and pirfenidone, modify disease progression, but IPF remains incurable and there is an urgent need for new therapies. We identified chitotriosidase (CHIT1) as new driver of fibrosis in IPF and a novel therapeutic target. We demonstrate that CHIT1 activity and expression are significantly increased in serum (3-fold) and induced sputum (4-fold) from IPF patients. In the lungs CHIT1 is expressed in a distinct subpopulation of profibrotic, disease-specific macrophages, which are only present in patients with ILDs and CHIT1 is one of the defining markers of this fibrosis-associated gene cluster. To define CHIT1 role in fibrosis, we used the therapeutic protocol of the bleomycin-induced pulmonary fibrosis mouse model. We demonstrate that in the context of chitinase induction and the macrophage-specific expression of CHIT1, this model recapitulates lung fibrosis in ILDs. Genetic inactivation of Chit1 attenuated bleomycin-induced fibrosis (decreasing the Ashcroft scoring by 28%) and decreased expression of profibrotic factors in lung tissues. Pharmacological inhibition of chitinases by OATD-01 reduced fibrosis and soluble collagen concentration. OATD-01 exhibited anti-fibrotic activity comparable to pirfenidone resulting in the reduction of the Ashcroft score by 32% and 31%, respectively. These studies provide a preclinical proof-of-concept for the antifibrotic effects of OATD-01 and establish CHIT1 as a potential new therapeutic target for IPF.
Collapse
Affiliation(s)
| | - Barbara A Dymek
- OncoArendi Therapeutics SA, 02-089, Warsaw, Poland; Postgraduate School of Molecular Medicine, Medical University of Warsaw, 02-097, Warsaw, Poland.
| | | | | | | | - Patrycja Nejman-Gryz
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | - Serdar Korur
- OncoArendi Therapeutics SA, 02-089, Warsaw, Poland
| | | | | | - Jan H von der Thüsen
- Department of Pathology, Erasmus Medical Center, 3015 GD, Rotterdam, the Netherlands
| | | | | | - Łukasz Cheda
- OncoArendi Therapeutics SA, 02-089, Warsaw, Poland
| | - Magdalena Paplinska-Goryca
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | - Małgorzata Proboszcz
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | | | - Katarzyna Górska
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | - Jakub Golab
- Department of Immunology, Medical University of Warsaw, 02-097, Warsaw, Poland
| | | | - Rafał Krenke
- Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland
| | | | | | | |
Collapse
|
3
|
Koralewski R, Dymek B, Mazur M, Sklepkiewicz P, Olejniczak S, Czestkowski W, Matyszewski K, Andryianau G, Niedziejko P, Kowalski M, Gruza M, Borek B, Jedrzejczak K, Bartoszewicz A, Pluta E, Rymaszewska A, Kania M, Rejczak T, Piasecka S, Mlacki M, Mazurkiewicz M, Piotrowicz M, Salamon M, Zagozdzon A, Napiorkowska-Gromadzka A, Bartlomiejczak A, Mozga W, Dobrzański P, Dzwonek K, Golab J, Nowotny M, Olczak J, Golebiowski A. Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis. J Med Chem 2020; 63:15527-15540. [PMID: 33078933 DOI: 10.1021/acs.jmedchem.0c01179] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase) are the enzymatically active chitinases that have been implicated in the pathology of chronic lung diseases such as asthma and interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis. The clinical and preclinical data suggest that pharmacological inhibition of CHIT1 might represent a novel therapeutic approach in IPF. Structural modification of an advanced lead molecule 3 led to the identification of compound 9 (OATD-01), a highly active CHIT1 inhibitor with both an excellent PK profile in multiple species and selectivity against a panel of other off-targets. OATD-01 given orally once daily in a range of doses between 30 and 100 mg/kg showed significant antifibrotic efficacy in an animal model of bleomycin-induced pulmonary fibrosis. OATD-01 is the first-in-class CHIT1 inhibitor, currently completed phase 1b of clinical trials, to be a potential treatment for IPF.
Collapse
Affiliation(s)
- Robert Koralewski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Barbara Dymek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Marzena Mazur
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Sylwia Olejniczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | | | - Gleb Andryianau
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Piotr Niedziejko
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michal Kowalski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Mariusz Gruza
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Bartłomiej Borek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karol Jedrzejczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Elżbieta Pluta
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Magdalena Kania
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Tomasz Rejczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Sylwia Piasecka
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michal Mlacki
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Michał Piotrowicz
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Magdalena Salamon
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | | | - Aneta Bartlomiejczak
- Structural Biology Center, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland
| | - Witold Mozga
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Paweł Dobrzański
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland.,Department of Immunology, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
| | - Marcin Nowotny
- Structural Biology Center, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
4
|
Andryianau G, Kowalski M, Piotrowicz MC, Rajkiewicz AA, Dymek B, Sklepkiewicz PL, Pluta E, Stefaniak F, Czestkowski W, Olejniczak S, Mazur M, Niedziejko P, Koralewski R, Matyszewski K, Gruza M, Zagozdzon A, Salamon M, Rymaszewska A, Welzer M, Dzwonek K, Golab J, Olczak J, Bartoszewicz A, Golebiowski A. Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. ACS Med Chem Lett 2020; 11:1228-1235. [PMID: 32551005 DOI: 10.1021/acsmedchemlett.0c00092] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Accepted: 04/24/2020] [Indexed: 01/06/2023] Open
Abstract
Human acidic mammalian chitinase (hAMCase) is one of two true chitinases in humans, the function of which remains elusive. In addition to the defense against highly antigenic chitin and chitin-containing pathogens in the gastric and intestinal contents, AMCase has been implicated in asthma, allergic inflammation, and ocular pathologies. Potent and selective small-molecule inhibitors of this enzyme have not been identified to date. Here we describe structural modifications of compound OAT-177, a previously developed inhibitor of mouse AMCase, leading to OAT-1441, which displays high activity and selectivity toward hAMCase. Significantly reduced off-target activity toward the human ether-à-go-go-related gene (hERG) and a good pharmacokinetic profile make OAT-1441 a potential candidate for further preclinical development as well as a useful tool compound to study the physiological role of hAMCase.
Collapse
Affiliation(s)
- Gleb Andryianau
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michal Kowalski
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Adam A. Rajkiewicz
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
- Centre of New Technologies, University of Warsaw, Banacha 2C, 02-097 Warsaw, Poland
| | - Barbara Dymek
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Elzbieta Pluta
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Filip Stefaniak
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
- Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology in Warsaw, Ks. Trojdena 4, 02-109 Warsaw, Poland
| | | | - Sylwia Olejniczak
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Marzena Mazur
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Piotr Niedziejko
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Robert Koralewski
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Mariusz Gruza
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Magdalena Salamon
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Mikolaj Welzer
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
- Department of Immunology, Medical University of Warsaw, Nielubowicza 5, 02-097 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Adam Golebiowski
- OncoArendi Therapeutics S.A., Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
5
|
Mazur M, Dymek B, Koralewski R, Sklepkiewicz P, Olejniczak S, Mazurkiewicz M, Piotrowicz M, Salamon M, Jędrzejczak K, Zagozdzon A, Czestkowski W, Matyszewski K, Borek B, Bartoszewicz A, Pluta E, Rymaszewska A, Mozga W, Stefaniak F, Dobrzański P, Dzwonek K, Golab J, Golebiowski A, Olczak J. Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases. J Med Chem 2019; 62:7126-7145. [PMID: 31291098 DOI: 10.1021/acs.jmedchem.9b00681] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Acidic mammalian chitinase (AMCase) and chitotriosidase-1 (CHIT1) are two enzymatically active proteins produced by mammals capable of cleaving the glycosidic bond in chitin. Based on the clinical findings and animal model studies, involvement of chitinases has been suggested in several respiratory system diseases including asthma, COPD, and idiopathic pulmonary fibrosis. Exploration of structure-activity relationships within the series of 1-(3-amino-1H-1,2,4-triazol-5-yl)-piperidin-4-amines, which was earlier identified as a scaffold of potent AMCase inhibitors, led us to discover highly active dual (i.e., AMCase and CHIT1) inhibitors with very good pharmacokinetic properties. Among them, compound 30 was shown to reduce the total number of cells in bronchoalveolar lavage fluid of mice challenged with house dust mite extract after oral administration (50 mg/kg, qd). In addition, affinity toward the hERG potassium channel of compound 30 was significantly reduced when compared to the earlier reported chitinase inhibitors.
Collapse
Affiliation(s)
- Marzena Mazur
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Barbara Dymek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Robert Koralewski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Piotr Sklepkiewicz
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Sylwia Olejniczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | - Michał Piotrowicz
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Magdalena Salamon
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Karol Jędrzejczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | | | | | - Bartłomiej Borek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | - Elżbieta Pluta
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | | | - Witold Mozga
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Filip Stefaniak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland.,Laboratory of Bioinformatics and Protein Engineering , International Institute of Molecular and Cell Biology in Warsaw , Ks. Trojdena 4 , 02-109 Warsaw , Poland
| | - Paweł Dobrzański
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland.,Department of Immunology , Medical University of Warsaw , Nielubowicza 5 , 02-097 Warsaw , Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101 , 02-089 Warsaw , Poland
| |
Collapse
|
6
|
Mazur M, Olczak J, Olejniczak S, Koralewski R, Czestkowski W, Jedrzejczak A, Golab J, Dzwonek K, Dymek B, Sklepkiewicz PL, Zagozdzon A, Noonan T, Mahboubi K, Conway B, Sheeler R, Beckett P, Hungerford WM, Podjarny A, Mitschler A, Cousido-Siah A, Fadel F, Golebiowski A. Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. J Med Chem 2018; 61:695-710. [PMID: 29283260 DOI: 10.1021/acs.jmedchem.7b01051] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
This article highlights our work toward the identification of a potent, selective, and efficacious acidic mammalian chitinase (AMCase) inhibitor. Rational design, guided by X-ray analysis of several inhibitors bound to human chitotriosidase (hCHIT1), led to the identification of compound 7f as a highly potent AMCase inhibitor (IC50 values of 14 and 19 nM against human and mouse enzyme, respectively) and selective (>150× against mCHIT1) with very good PK properties. This compound dosed once daily at 30 mg/kg po showed significant anti-inflammatory efficacy in HDM-induced allergic airway inflammation in mice, reducing inflammatory cell influx in the BALF and total IgE concentration in plasma, which correlated with decrease of chitinolytic activity. Therapeutic efficacy of compound 7f in the clinically relevant aeroallergen-induced acute asthma model in mice provides a rationale for developing AMCase inhibitor for the treatment of asthma.
Collapse
Affiliation(s)
- Marzena Mazur
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Sylwia Olejniczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Robert Koralewski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Anna Jedrzejczak
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland.,Department of Immunology, Medical University of Warsaw , 1A Banacha Str., 02-097 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Barbara Dymek
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | | | - Tom Noonan
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Keyvan Mahboubi
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Bruce Conway
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Ryan Sheeler
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Paul Beckett
- The Institute for Pharmaceutical Discovery , Business Drive 23, Branford, Connecticut 06405, United States
| | - William M Hungerford
- The Institute for Pharmaceutical Discovery , Business Drive 23, Branford, Connecticut 06405, United States
| | - Alberto Podjarny
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Andre Mitschler
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Alexandra Cousido-Siah
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Firas Fadel
- Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg , 1 Rue Laurent Fries, 67404 Illkirch, France
| | - Adam Golebiowski
- OncoArendi Therapeutics SA , Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
7
|
Mazur M, Bartoszewicz A, Dymek B, Salamon M, Andryianau G, Kowalski M, Olejniczak S, Matyszewski K, Pluta E, Borek B, Stefaniak F, Zagozdzon A, Mazurkiewicz M, Koralewski R, Czestkowski W, Piotrowicz M, Niedziejko P, Gruza MM, Dzwonek K, Golebiowski A, Golab J, Olczak J. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. Bioorg Med Chem Lett 2017; 28:310-314. [PMID: 29292229 DOI: 10.1016/j.bmcl.2017.12.047] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2017] [Revised: 12/08/2017] [Accepted: 12/21/2017] [Indexed: 12/17/2022]
Abstract
This article describes our work towards the identification of a potent and selective inhibitor of mouse chitotriosidase (mCHIT1). A series of small molecule inhibitors of mCHIT1 and mAMCase have been developed from early lead compound 1. Examination of synthetized analogues led to discovery of several novel highly potent compounds. Among them compound 9 (OAT-2068) displays a remarkable 143-fold mCHIT1 vs. mAMCase selectivity. To explain the observed SAR molecular docking experiments were performed, which were in line with the experimental data from the enzymatic assays. Inhibitor 9 (OAT-2068) was found to have an excellent pharmacokinetic profile. This, together with high activity and selectivity, makes the compound an ideal and unique tool for studying the role of CHIT1 in biological models.
Collapse
Affiliation(s)
- Marzena Mazur
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Barbara Dymek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Magdalena Salamon
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Gleb Andryianau
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Michał Kowalski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Sylwia Olejniczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Elżbieta Pluta
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Bartłomiej Borek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Filip Stefaniak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland; Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology in Warsaw, Ks. Trojdena 4, 02-109 Warsaw, Poland
| | | | | | - Robert Koralewski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | | | - Michał Piotrowicz
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Piotr Niedziejko
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Mariusz M Gruza
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Karolina Dzwonek
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Adam Golebiowski
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| | - Jakub Golab
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland; Department of Immunology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland
| | - Jacek Olczak
- OncoArendi Therapeutics SA, Żwirki i Wigury 101, 02-089 Warsaw, Poland
| |
Collapse
|
8
|
Perlikowska R, Piekielna J, Mazur M, Koralewski R, Olczak J, do Rego JC, Fichna J, Modranka J, Janecki T, Janecka A. Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2. Bioorg Med Chem 2014; 22:4803-9. [DOI: 10.1016/j.bmc.2014.06.056] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Revised: 06/23/2014] [Accepted: 06/30/2014] [Indexed: 10/25/2022]
|